Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer

Prostate Cancer and Prostatic Diseases volume 15, pages 144–149 (2012)Cite this article

Abstract

Background:

We would like to compare the different RNASEL genotypes with the stage of the cancer using parameters such as PSA levels, Gleason score and T-stage, and to develop a clinical protocol for the monitoring of the disease for trying a better evolution of the patient.

Methods:

A total of 231 patients with sporadic prostate cancer and 100 of controls were genotyped in RNASEL gene by sequencing the exons 1 and 3. A survey of clinical information was collected by a specialist following the Helsinki protocol. All patients and controls were interviewed by a researcher and signed their informed consent to participation in the study, which was approved by Ethics Committee of the hospital. The genetic information was processed and collected with an ABI PRISM Genetic Analyser 3130 using SeqScape software v.2.6. All the patients were analysed by comparing the genetic and clinical data. χ2-tests, Monte Carlo, Fisher tests and contigency tables were performed using SPSS v.15.0 and ARLEQUIN v.3.5 software on patient population.

Results:

Significant differences were found only between patients and controls in D541E, R461Q and I97L genotypes, the remainder of the variants did not seem relevant to our population in contrast to other populations, such as north-Caucasians, Afro Americans and Ashkenazi Jews. The genotypes associated with the worst prognoses are G/G in D541E, A/A in R462Q and A/G in I97L. The controls were included in our study to determine an approximation of the genotype in our population compared with the patients, but they did not account for the statistical process.

Conclusions:

The genetic profile of patients with this cancer combined with other parameters could be used as a prognosis factor in deciding to give more radical and frequent treatments, depending on personal genotype.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009; 15: 7582–7592.

    Article  CAS  Google Scholar 

  2. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006; 66: 2000–2011.

    Article  CAS  Google Scholar 

  3. Giménez-Bachs JM, Salinas-Sánchez AS, Sánchez-Sánchez F, Lorenzo-Romero JG, Donate-Moreno MJ, Pastor-Navarro H et al. Determination of vhl gene mutations in sporadic renal cell carcinoma. Eur Urol 2006; 49: 1051–1057.

    Article  Google Scholar 

  4. FitzGerald LM, Patterson B, Thomson R, Polanowski A, Quinn S, Brohede J et al. Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur J Hum Genet 2009; 17: 368–377.

    Article  CAS  Google Scholar 

  5. Alberti C . Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features. Eur Rev Med Pharmacol Sci 2010; 14: 31–41.

    CAS  PubMed  Google Scholar 

  6. Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007; 13: 5959–5964.

    Article  CAS  Google Scholar 

  7. Wiklund F, Jonsson B, Brookes AJ, Strömqvist L, Adolfsson J, Emanuelsson M et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004; 10: 7150–7156.

    Article  CAS  Google Scholar 

  8. Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J et al. The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Familial Cancer 2006; 5: 389–395.

    Article  CAS  Google Scholar 

  9. Beuten J, Gelfond JAL, Franke JL, Shook S, Johnson-Pais TL, Thompson IM et al. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 2010; 19: 588–599.

    Article  CAS  Google Scholar 

  10. Maier C, Haeusler J, Herkommer K, Vesovic Z, Hoegel J, Vogel W et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 2005; 92: 1159–1164.

    Article  CAS  Google Scholar 

  11. Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN, Yatani R . Comparative studies of prostate cancer in Japan versus the United States: A review. Urol Oncol 2000; 5: 274–283.

    Article  CAS  Google Scholar 

  12. Godoy G, Huang GJ, Patel T, Taneja SS . Long-term follow-up of men with isolated high-grade prostatic intra-epithelial neoplasia followed by serial delayed interval biopsy. Urology 2011; 77: 669–674.

    Article  Google Scholar 

  13. Excoffier L, Lischer HEL . Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resources (Arlequin suite ver 3.5) 2010; 10: 564–567.

    Article  Google Scholar 

  14. Agalliu I, Leanza SM, Smith L, Trent JM, Carpten JD, Bailey-Wilson JE et al. Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Prostate 2010; 70: 1716–1727.

    Article  CAS  Google Scholar 

  15. Li H, Tai BC . RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006; 12: 5713–5719.

    Article  CAS  Google Scholar 

  16. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 581–583.

    Article  CAS  Google Scholar 

  17. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H . Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 2003; 89: 691–696.

    Article  CAS  Google Scholar 

  18. Rennert H, Zeigler-Johnson C, Devi Mittal R, Tan Y, Sadowl CM, Edwards J et al. Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. Urology 2009; 72: 456–460.

    Article  Google Scholar 

  19. Noonan-Wheeler FC, Wu W, Roehl KA, Kim A, Haugen J, Suarez BK et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate 2006; 66: 49–56.

    Article  CAS  Google Scholar 

  20. Summers K, Crespi B . Molecular evolution of the prostate cancer susceptibility locus RNASEL: evidence for positive selection. Infect Genet Evol 2008; 8: 297–301.

    Article  CAS  Google Scholar 

  21. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71: 981–984.

    Article  Google Scholar 

  22. Rökman A, Ikonen T, Seppälä EH, Nupponen N, Autio V, Mononen N et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 70: 1299–1304.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Legal Medicine and Toxicology Department, Laboratory of Genetic Identification, Facultad de Medicina, Universidad de Granada, Granada, Spain

    M J Alvarez-Cubero, J C Alvarez & J A Lorente

  2. R & D Division, LORGEN GP, PT, Ciencias de la Salud - BIC, Granada, Spain

    C Entrala & F Fernandez-Rosado

  3. Pfizer Center, University of Granada, Junta of Andalucia of Genomics and Oncology Research, Biomedical Research Center, Av. del Conocimiento s/n, Granada, Spain

    L J Martinez-Gonzalez, J C Alvarez & J A Lorente

  4. Service of Urology, Universitary Hospital Virgen de las Nieves, Granada, Spain

    A Suarez & J M Cozar

Authors
  1. M J Alvarez-Cubero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Entrala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Fernandez-Rosado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L J Martinez-Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J C Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Suarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J A Lorente
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J M Cozar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M J Alvarez-Cubero.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alvarez-Cubero, M., Entrala, C., Fernandez-Rosado, F. et al. Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer. Prostate Cancer Prostatic Dis 15, 144–149 (2012). https://doi.org/10.1038/pcan.2011.56

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.56

Keywords

This article is cited by

Search

Advanced search

Quick links